Kour, S., Rana, S., Contreras, J. I., King, H. M., Robb, C. M., Sonawane, Y. A., . . . Natarajan, A. (2019). CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Mol Pharmacol.
Citação norma ChicagoKour, Smit, et al. "CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax." Mol Pharmacol 2019.
Citação norma MLAKour, Smit, et al. "CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax." Mol Pharmacol 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.